Specific NK cell activation to treat relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients – final, updated data on clinical outcome, pharmacokinetics and pharmacodynamics of a phase 1 study investigating AFM13, a bispecific anti- CD30/CD16A TandAb
Rothe et al.
ASH 2014